Recursion Pharmaceuticals, Inc. RXRX Accrued Contingent Liabilities
Accrued Contingent Liabilities at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LossContingencyAccrualAtCarryingValue.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
The Company has agreed to indemnify its officers and directors for certain events or occurrences, while the officer or director is or was serving at the Company’s request in such capacity. The Company purchases directors and officers liability insurance coverage that provides for reimbursement to the Company for covered obligations and this is intended to limit the Company’s exposure and enable it to recover a portion of any amount it pays under its indemnification obligations. The Company had no liabilities recorded for these agreements as of June 30, 2026 and December 31, 2025, as no amounts were probable.
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s accrued contingent liabilities?
- Recursion Pharmaceuticals, Inc. (RXRX) reported accrued contingent liabilities of $0 in Q2 2026.
- What does accrued contingent liabilities mean?
- Liabilities that are uncertain as to their existence or amount, and are accrued based on probability and estimability.
Ask your AI about Recursion Pharmaceuticals, Inc.'s accrued contingent liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
